ET-18-OCH3 (edelfosine): a selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 death receptor.
about
Exogenous ether lipids predominantly target mitochondriaCell membrane modulation as adjuvant in cancer therapyThe orally available, synthetic ether lipid edelfosine inhibits T cell proliferation and induces a type I interferon responsePhospholipase C and myosin light chain kinase inhibition define a common step in actin regulation during cytokinesisVitamin E prevents lipid raft modifications induced by an anti-cancer lysophospholipid and abolishes a Yap1-mediated stress response in yeast.Lipid raft-targeted therapy in multiple myeloma.The SK3/K(Ca)2.3 potassium channel is a new cellular target for edelfosine.Involvement of lipid rafts in the localization and dysfunction effect of the antitumor ether phospholipid edelfosine in mitochondria.Endoplasmic reticulum targeting in Ewing's sarcoma by the alkylphospholipid analog edelfosineMechanisms of action of lysophospholipid analogues against trypanosomatid parasites.Drug uptake, lipid rafts, and vesicle trafficking modulate resistance to an anticancer lysophosphatidylcholine analogue in yeastThe therapeutic implications of clinically applied modifiers of heat shock protein 70 (Hsp70) expression by tumor cells.Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines.Glycosidated phospholipids: uncoupling of signalling pathways at the plasma membrane.Lipid rafts and clusters of apoptotic signaling molecule-enriched rafts in cancer therapy.The role of phosphatidylcholine and choline metabolites to cell proliferation and survival.Lipid rafts and raft-mediated supramolecular entities in the regulation of CD95 death receptor apoptotic signaling.Caenorhabditis elegans as a platform to study the mechanism of action of synthetic antitumor lipidsAntitumor alkyl-lysophospholipid analog edelfosine induces apoptosis in pancreatic cancer by targeting endoplasmic reticulum.Synthesis and antitumor activity of ether glycerophospholipids bearing a carbamate moiety at the sn-2 position: selective sensitivity against prostate cancer cell lines.A glycosylated antitumor ether lipid kills cells via paraptosis-like cell death.Mitochondrial-derived ROS in edelfosine-induced apoptosis in yeasts and tumor cells.Ethanol-induced apoptosis in polarized hepatic cells possibly through regulation of the Fas pathway.Combination of the anti-tumour cell ether lipid edelfosine with sterols abolishes haemolytic side effects of the drug.Necroptosis is associated with low procaspase-8 and active RIPK1 and -3 in human glioma cells.nsPEF-induced PIP2 depletion, PLC activity and actin cytoskeletal cortex remodeling are responsible for post-exposure cellular swelling and blebbing.Lipid raft-mediated Akt signaling as a therapeutic target in mantle cell lymphomaLipid raft involvement in yeast cell growth and death.Multivariate statistical differentiation of renal cell carcinomas based on lipidomic analysis by ambient ionization imaging mass spectrometry.Targeting Brain-Adaptive Cancer Stem Cells Prohibits Brain Metastatic Colonization of Triple-Negative Breast Cancer.Synthesis of Bioconjugate Sesterterpenoids with Phospholipids and Polyunsaturated Fatty Acids.Differential Targets and Subcellular Localization of Antitumor Alkyl-lysophospholipid in LeukemicVersusSolid Tumor Cells
P2860
Q27309030-78839928-DD23-40CE-B293-88C7C4877FF9Q28078167-152691D2-CCFA-4424-8974-064C07D386F0Q28541466-58FBE650-1A34-457E-88C0-8702951717EEQ30479562-D0FF4312-6FE7-497A-93F3-BB4C181FC5C5Q34055979-B4DDF1BE-2B21-41C8-98B6-44616FB98D77Q34112080-D7836306-138E-4687-BBC7-16592DD21C6AQ34540226-36A737DF-427A-4870-A63A-8D3059A6A4D1Q35064991-12D7790F-0317-47AD-994B-ACA8E327DF58Q35987417-7FFAAD43-FF6D-4BC5-BFEA-A9ABA275A855Q36576096-10DFF75C-C1A8-4C92-A27A-219BFB6D97DBQ36708592-E9541B27-6658-4BCD-A7AB-3EB6B38B0A9FQ37112632-6EE687B1-5839-44B8-8897-D06F73CE0AB7Q37555298-2FB1D811-802C-447E-93D5-7F465C21FF42Q37717757-98732C87-62E3-486D-B510-6C99D4BA4010Q37750797-D3553F11-D164-4305-9F9A-9872C2A5C68CQ38076754-BFC4899E-328D-423E-AA70-DFF0631D7888Q38363543-39F66D13-FA1D-4304-8612-8764FB91DE1DQ38931076-2BAA09CD-3986-40F7-80FF-E7D4C017AC49Q39447548-EC747B6F-1F1F-44F1-84E1-8208DDE7CF02Q39695428-65F5D02E-2DB7-4207-9669-C19FCE64E803Q39860456-84FA25C4-80A3-4DF7-B8CF-24B24BE71DAEQ40132217-A4AE80DF-CAB5-4E80-A82E-F1A60DB59BF8Q40215232-0625AD60-8582-46C2-8B4F-1B738283C771Q41372981-8A2FE43E-C31F-41EF-9BFB-490856B0FBCAQ41575088-E68B90F8-FB85-4822-8403-896B2E85DB1BQ41682495-5261422B-761F-403E-96D0-6AF3D763B926Q42142419-586E2D7A-5A1B-448C-81B1-0ED277EC90CEQ42433327-C602B2A2-8D23-421C-9356-86B66C0582CBQ42856234-DAAB44D5-145B-46C5-BAB9-CB1018AD5016Q52641846-0E103C59-DF03-428F-8633-C0B385E4A0FBQ54322820-EC03CFDB-1580-4975-B99B-80EFC6380367Q57372438-C22C3F3C-EE8F-422A-AE40-6AB83BFF4262
P2860
ET-18-OCH3 (edelfosine): a selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 death receptor.
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
ET-18-OCH3 (edelfosine): a sel ...... on of Fas/CD95 death receptor.
@ast
ET-18-OCH3 (edelfosine): a sel ...... on of Fas/CD95 death receptor.
@en
type
label
ET-18-OCH3 (edelfosine): a sel ...... on of Fas/CD95 death receptor.
@ast
ET-18-OCH3 (edelfosine): a sel ...... on of Fas/CD95 death receptor.
@en
prefLabel
ET-18-OCH3 (edelfosine): a sel ...... on of Fas/CD95 death receptor.
@ast
ET-18-OCH3 (edelfosine): a sel ...... on of Fas/CD95 death receptor.
@en
P2093
P356
P1476
ET-18-OCH3 (edelfosine): a sel ...... on of Fas/CD95 death receptor.
@en
P2093
Consuelo Gajate
Faustino Mollinedo
Federico Gago
P304
P356
10.2174/0929867043363703
P577
2004-12-01T00:00:00Z